Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

BACKGROUND: Clinical guidelines generally recommend endocrine therapy (ET) as first-line treatment of hormone receptor-positive advanced breast cancer (HR+ ABC) whereas chemotherapy (CT) should be considered in the presence of life-threatening disease or limited clinical benefit after three sequenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yun, Han, Yiqun, Yu, Pei, Ouyang, Quchang, Yan, Min, Wang, Xiaojia, Hu, Xichun, Jiang, Zefei, Huang, Tao, Tong, Zhongsheng, Wang, Shusen, Yin, Yongmei, Li, Hui, Yang, Runxiang, Yang, Huawei, Teng, Yuee, Sun, Tao, Cai, Li, Li, Hongyuan, Chen, Xi, He, Jianjun, Liu, Xinlan, Yang, Shune, Qiao, Youlin, Fan, Jinhu, Wang, Jiayu, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905089/
https://www.ncbi.nlm.nih.gov/pubmed/33643905
http://dx.doi.org/10.3389/fonc.2020.599604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905089/
https://www.ncbi.nlm.nih.gov/pubmed/33643905
http://dx.doi.org/10.3389/fonc.2020.599604

Ejemplares similares